The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesDevelopment of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIVHIV-1 neutralizing antibodies: understanding nature's pathwaysAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesExpression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccinesDNA vaccines against human immunodeficiency virus type 1.An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand bindingLimited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesProtection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsBiologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsComparing antigenicity and immunogenicity of engineered gp120.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesEnvelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challengeStabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvantsEffects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particlesChanges in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable regionHIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesRecombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbsPrime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
P2860
Q24561905-32CA6A44-3D66-48B2-ABE8-A54FB5FC4D9EQ24797123-D5D28862-1C54-408C-9C7A-44AEABB7E8A0Q27000480-AA158D70-3A0A-4B3E-BA77-F12BB654CCCCQ27489000-9ED667DC-4FA6-4C0B-8978-71CF1C61A388Q28730561-88B92931-8ED9-4B3A-AD53-4A75BFA24DCDQ28732438-2F6940A6-C232-4F2C-8E0F-8F23E120A456Q28743092-FAF2A53E-446E-4E59-B124-73C20342CFECQ29307502-0C2A1694-E75C-470C-B55A-901A9A2CD2FFQ29619015-58393863-5205-4DD3-8C86-C5EBA12B1C7CQ30332833-7BE3F323-8EBE-4629-9CD4-83FAFE6334FDQ30342130-53926D2C-02DE-4E6A-80A0-F4E39D7AF71FQ30375785-7C2B562E-3811-469A-B9D5-CD340A0B7482Q30379200-09392F38-1E88-4D9A-90D0-77958D3F2C38Q30381447-D03DB24D-6DDA-4ED0-854D-220F3AA10D62Q30499590-40DB8021-5505-436A-9691-E6228284DF4CQ31138949-F945ED8C-3FAA-4E99-80E3-C3F36DDCF597Q33601372-C30D280E-E38A-47CB-8489-FAE420D9C585Q33648910-3CC484C7-63CC-4EF2-9C29-69A5DDE9B2C5Q33737723-54D1C8AA-B9BA-4101-84B1-52B77666E591Q33780524-3440792C-1CE9-44C2-8563-06D2A7DC93F6Q33883887-D8172C5A-AD61-4E94-A28B-D306B8BEE0F2Q33911986-365BA130-6624-44A6-A2F0-605CAEB9F346Q33930424-F5B44ED7-5139-4EF3-B487-B38F305B25DFQ33960361-53348FB4-C2D9-4362-A435-0E1EF6732B4CQ33984309-3416B0B7-BE66-48E8-BEBB-F6CF895B0668Q34128200-C5DA4EC0-B233-4953-8DB8-BA757BF8F8D2Q34154514-B77024B2-8737-4DA3-BB40-173E3FFD5DE3Q34178259-E80FCF59-D57D-47BF-B7E4-227040AA7D9BQ34299053-6CFAC203-5401-4FBA-96EB-4C320EC21632Q34302085-D5B32DE0-5721-432F-BC71-C67FDA715927Q34326453-A5B1AB5B-9EBF-4D9F-801D-FD5F85EC6C96Q34332284-1D6AC987-EA50-4ADA-ADBF-E92ECDDDFFE5Q34332728-0C4D5E3F-295F-4B13-B19A-1D7ED3D34A63Q34344205-22325064-33A8-4E96-9AF3-E6825360A701Q34361680-D4894F52-9E16-4075-8F4A-EF7FB376B472Q34465510-DFC70A6F-085B-441E-A76F-8C4223C5B66CQ34471760-24957911-C546-487B-AA13-13888CD7F193Q34477471-F197D7B0-C225-4234-B7EC-1A105CB4FDC3Q34539819-2EDB2A0E-32B3-4FB8-BC44-DD1DCD5C75B5Q34551010-B294AAEE-E021-4A73-8EC3-BC9F5AD0D25D
P2860
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
The ability of an oligomeric h ...... he second hypervariable region
@en
The ability of an oligomeric human immunodeficiency virus type 1
@nl
type
label
The ability of an oligomeric h ...... he second hypervariable region
@en
The ability of an oligomeric human immunodeficiency virus type 1
@nl
prefLabel
The ability of an oligomeric h ...... he second hypervariable region
@en
The ability of an oligomeric human immunodeficiency virus type 1
@nl
P2093
P2860
P1433
P1476
The ability of an oligomeric h ...... he second hypervariable region
@en
P2093
I Mboudjeka
I Srivastava
J Blanchard
J R Mascola
P2860
P304
P356
10.1128/JVI.75.12.5526-5540.2001
P407
P577
2001-06-01T00:00:00Z